

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

NCT07152223

Status	RECRUITING
Phase	Not Applicable
Sponsor	Guangzhou Bio-gene Technology Co., Ltd
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (13)

- Good compliance: The patient or their guardian understands and voluntarily signs the informed consent form, and it is expected that all documents, procedures, follow-up examinations and treatments stipulated in the study can be completed.
 - Previously diagnosed with one of the following diseases and meeting the corresponding latest international classification/diagnostic criteria :
 - Systemic lupus erythematosus (SLE);
 - Rheumatoid arthritis (RA);
 - Systemic sclerosis (SSc) ;
- ... and 8 more (see full listing online)

Exclusion (14)

- Intracranial hypertension or confusion;
 - Symptomatic heart failure or severe arrhythmia;
 - Respiratory failure;
 - Accompanied by other types of malignant tumors;
 - Diffuse vascular coagulation;
- ... and 9 more (see full listing online)

Locations (1 total)

Dongguan Taixin Hospital, Dongguan, Guangdong, China